Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T19:53:00.555Z.
Calculation as of: 2026-10-06T19:53:00.555Z.
Quote observation: 2026-10-06T19:50:33.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 47811cd6fce140e68777d2609bf88a35ade871fb75fdb0cf4ca3c33c868081b2
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Medicus Pharma Ltd. Common Stock
Market Cap
$10.10M
EV/EBITDA Ratio
N/A
| NAME | MARKET CAP | EV/EBITDA RATIO |
|---|---|---|
| Medicus Pharma Ltd. Common Stock (MDCX) | $10.10M | N/A |
| Tvardi Therapeutics, Inc. (TVRD)vs › | $10.18M | N/A |
| Valion Bio, Inc. (VBIO)vs › | $9.98M | N/A |
| Satellos Bioscience Inc. (MSLE)vs › | $9.92M | N/A |
| Senti Biosciences, Inc. (SNTI)vs › | $9.97M | N/A |
| Ainos, Inc. (AIMD)vs › | $9.79M | N/A |
| CytoMed Therapeutics Limited (GDTC)vs › | $11.13M | N/A |
| Polyrizon Ltd. (PLRZ)vs › | $10.52M | N/A |
| NeuroOne Medical Technologies Corporation (NMTC)vs › | $9.66M | N/A |
| MetaVia Inc. (MTVA)vs › | $9.62M | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
